Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
“Hear, hear”.... I don’t normally drop in next door but thought I’d rub in some excess fish and chip salt in to the wounds and then binge on homes under the hammer lol
Maybe it was pre-recorded as the Q&A didn't seem to happen.
David Wilsons even is live @ 5.00?
@PL75, haha, yes was there in June, plenty of newbies though, and really good history lesson!
GLA
Klaus ...
Specificity overlooked, 95% (implied) not good enough.
David ...
Best tests - high sens / spec. Antigen test the bias will be sens and neg predictive value, ideally both (sens / spec) high.
Klaus ..
Agrees, don't want false negatives. Spec a big hurdle.
GLA
Who is going to tell LLnP?
Klaus ...
Need Sens and Spec better than before, better than one's on the market.
Many surprises appearing in (implied) nature of virus.
Darren (Sona) ...
Seems to have said not yet achieved acceptable level of detection?
GLA
Brendan again.
Risk of accelerated process.
Need proper development methodology (that's what DCN do - Cytiva competitor).
Need to adapt to changing use and performance requirements.
One of biggest gaps is knowledge, e.g. scaling manufacturing (good that we have BBI and Abingdon).
Time to result critical - benefit of LFT - result in minutes. Particularly antigen testing.
Mass pop screening in US - LFT provides only available solution.
GLA
Really? Well thats pointless glad I havnt bothered to watch.
No it is definitely the presentation from back in June
sounds like a new one to me more relevant to where they are today, perhaps I'm wrong
Darren Rowles - Sona
Mentioned the Avacta test before the Sona one - which is Nasopharyngeal swab (he's a bitworried!).
CMO (contract manufacturing organisations) a constraint. Tech transfer normally 6 months. Anticipates 100's millions of tests.
GLA
This is a replay of the presentation hosted back in June - nothing new. It will be interesting if the Q&A is a replay too or if others will be available to answer real time questions.
I think you have to sign up - but here is my link:
https://events.labroots.com/event/DiagnosticsVirtualSummitAglobalperspective/en-us#!/Auditorium/n890690
https://events.labroots.com/event/DiagnosticsVirtualSummitAglobalperspective/en-us#!/Auditorium/n890690
Registration required.
David Wilson (Awacta) ...
Need test that can b easily deployed in community, primary care and consumer settings.
LFT the only format for mass screening.
Demand for testing will not go away for a long time, testing in significant numbers for at least 12 months.
FDA and MHRA looking to accelerate approval process (yes, he said FDA).
Without these tools (LFT tests) will be difficult to get society back to normal.
Because of demand, supply under strain - tests, components - supply-chain under strain.
GLA
Can you share a link?
Great intro from Brendan O'Farrell - DCN. Klaus just confirming confirming (as said by Brendan) antibody tests not the way to go. Need antigen tests, but warning about 'user errors' in self-sample test . Need sensitivity better than 95%.
Will need to test for a very long time.
This is good stuff. David on now.
GLA
GLA